Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs121434568

Current Build 155

Released April 9, 2021

Organism
Homo sapiens
Position
chr7:55191822 (GRCh38.p13) Help

The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.

Alleles
T>A / T>G
Variation Type
SNV Single Nucleotide Variation
Frequency
G=0.00004 (3/78700, PAGE_STUDY)
G=0.000 (0/660, ALFA)
Clinical Significance
Reported in ClinVar
Gene : Consequence
EGFR : Missense Variant
Publications
49 citations
Genomic View
See rs on genome
Help

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements
Sequence name Change
GRCh38.p13 chr 7 NC_000007.14:g.55191822T>A
GRCh38.p13 chr 7 NC_000007.14:g.55191822T>G
GRCh37.p13 chr 7 NC_000007.13:g.55259515T>A
GRCh37.p13 chr 7 NC_000007.13:g.55259515T>G
EGFR RefSeqGene (LRG_304) NG_007726.3:g.177791T>A
EGFR RefSeqGene (LRG_304) NG_007726.3:g.177791T>G
Gene: EGFR, epidermal growth factor receptor (plus strand)
Molecule type Change Amino acid[Codon] SO Term
EGFR transcript variant 2 NM_201282.2:c. N/A Genic Downstream Transcript Variant
EGFR transcript variant 3 NM_201283.2:c. N/A Genic Downstream Transcript Variant
EGFR transcript variant 4 NM_201284.2:c. N/A Genic Downstream Transcript Variant
EGFR transcript variant 1 NM_005228.5:c.2573T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform a precursor NP_005219.2:p.Leu858Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant 1 NM_005228.5:c.2573T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform a precursor NP_005219.2:p.Leu858Arg L (Leu) > R (Arg) Missense Variant
EGFR transcript variant 6 NM_001346898.2:c.2573T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform f precursor NP_001333827.1:p.Leu858Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant 6 NM_001346898.2:c.2573T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform f precursor NP_001333827.1:p.Leu858Arg L (Leu) > R (Arg) Missense Variant
EGFR transcript variant EGFRvIII NM_001346941.2:c.1772T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform i precursor NP_001333870.1:p.Leu591Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant EGFRvIII NM_001346941.2:c.1772T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform i precursor NP_001333870.1:p.Leu591Arg L (Leu) > R (Arg) Missense Variant
EGFR transcript variant 8 NM_001346900.2:c.2414T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform h NP_001333829.1:p.Leu805Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant 8 NM_001346900.2:c.2414T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform h NP_001333829.1:p.Leu805Arg L (Leu) > R (Arg) Missense Variant
EGFR transcript variant 5 NM_001346897.2:c.2438T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform e precursor NP_001333826.1:p.Leu813Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant 5 NM_001346897.2:c.2438T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform e precursor NP_001333826.1:p.Leu813Arg L (Leu) > R (Arg) Missense Variant
EGFR transcript variant 7 NM_001346899.2:c.2438T>A L [CTG] > Q [CAG] Coding Sequence Variant
epidermal growth factor receptor isoform g precursor NP_001333828.1:p.Leu813Gln L (Leu) > Q (Gln) Missense Variant
EGFR transcript variant 7 NM_001346899.2:c.2438T>G L [CTG] > R [CGG] Coding Sequence Variant
epidermal growth factor receptor isoform g precursor NP_001333828.1:p.Leu813Arg L (Leu) > R (Arg) Missense Variant
Help

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: A (allele ID: 363160 )
ClinVar Accession Disease Names Clinical Significance
RCV000419082.1 Non-small cell lung cancer Likely-Pathogenic
Allele: G (allele ID: 31648 )
ClinVar Accession Disease Names Clinical Significance
RCV000018083.89 Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic Drug-Response
RCV000018084.63 Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic Drug-Response
RCV000150629.1 Tyrosine kinase inhibitor response Drug-Response
RCV000211235.1 carboplatin, docetaxel, erlotinib, gemcitabine, and paclitaxel response - Efficacy Drug-Response
RCV000211323.1 gefitinib response - Efficacy Drug-Response
RCV000211410.1 erlotinib response - Efficacy Drug-Response
RCV000418019.1 Lung adenocarcinoma Likely-Pathogenic
RCV000435684.1 Non-small cell lung cancer Pathogenic
RCV000987885.1 Lung carcinoma Pathogenic
RCV001030016.1 Gefitinib response Drug-Response
RCV001030017.1 Erlotinib response Drug-Response

ALFA Allele Frequency (New)
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20201027095038
Population Group Sample Size Ref Allele Alt Allele
Total Global 660 T=1.000 G=0.000
European Sub 78 T=1.00 G=0.00
African Sub 434 T=1.000 G=0.000
African Others Sub 0 T=0 G=0
African American Sub 434 T=1.000 G=0.000
Asian Sub 34 T=1.00 G=0.00
East Asian Sub 34 T=1.00 G=0.00
Other Asian Sub 0 T=0 G=0
Latin American 1 Sub 0 T=0 G=0
Latin American 2 Sub 0 T=0 G=0
South Asian Sub 6 T=1.0 G=0.0
Other Sub 108 T=1.000 G=0.000


Help

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download
Study Population Group Sample Size Ref Allele Alt Allele
The PAGE Study Global Study-wide 78700 T=0.99996 G=0.00004
The PAGE Study AfricanAmerican Sub 32514 T=1.00000 G=0.00000
The PAGE Study Mexican Sub 10810 T=1.00000 G=0.00000
The PAGE Study Asian Sub 8318 T=0.9999 G=0.0001
The PAGE Study PuertoRican Sub 7918 T=0.9997 G=0.0003
The PAGE Study NativeHawaiian Sub 4534 T=1.0000 G=0.0000
The PAGE Study Cuban Sub 4230 T=1.0000 G=0.0000
The PAGE Study Dominican Sub 3828 T=1.0000 G=0.0000
The PAGE Study CentralAmerican Sub 2450 T=1.0000 G=0.0000
The PAGE Study SouthAmerican Sub 1982 T=1.0000 G=0.0000
The PAGE Study NativeAmerican Sub 1260 T=1.0000 G=0.0000
The PAGE Study SouthAsian Sub 856 T=1.000 G=0.000
Help

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement T= A G
GRCh38.p13 chr 7 NC_000007.14:g.55191822= NC_000007.14:g.55191822T>A NC_000007.14:g.55191822T>G
GRCh37.p13 chr 7 NC_000007.13:g.55259515= NC_000007.13:g.55259515T>A NC_000007.13:g.55259515T>G
EGFR RefSeqGene (LRG_304) NG_007726.3:g.177791= NG_007726.3:g.177791T>A NG_007726.3:g.177791T>G
EGFR transcript variant 1 NM_005228.5:c.2573= NM_005228.5:c.2573T>A NM_005228.5:c.2573T>G
EGFR transcript variant 1 NM_005228.4:c.2573= NM_005228.4:c.2573T>A NM_005228.4:c.2573T>G
EGFR transcript variant 1 NM_005228.3:c.2573= NM_005228.3:c.2573T>A NM_005228.3:c.2573T>G
EGFR transcript variant 7 NM_001346899.2:c.2438= NM_001346899.2:c.2438T>A NM_001346899.2:c.2438T>G
EGFR transcript variant 7 NM_001346899.1:c.2438= NM_001346899.1:c.2438T>A NM_001346899.1:c.2438T>G
EGFR transcript variant 8 NM_001346900.2:c.2414= NM_001346900.2:c.2414T>A NM_001346900.2:c.2414T>G
EGFR transcript variant 8 NM_001346900.1:c.2414= NM_001346900.1:c.2414T>A NM_001346900.1:c.2414T>G
EGFR transcript variant EGFRvIII NM_001346941.2:c.1772= NM_001346941.2:c.1772T>A NM_001346941.2:c.1772T>G
EGFR transcript variant EGFRvIII NM_001346941.1:c.1772= NM_001346941.1:c.1772T>A NM_001346941.1:c.1772T>G
EGFR transcript variant 6 NM_001346898.2:c.2573= NM_001346898.2:c.2573T>A NM_001346898.2:c.2573T>G
EGFR transcript variant 6 NM_001346898.1:c.2573= NM_001346898.1:c.2573T>A NM_001346898.1:c.2573T>G
EGFR transcript variant 5 NM_001346897.2:c.2438= NM_001346897.2:c.2438T>A NM_001346897.2:c.2438T>G
EGFR transcript variant 5 NM_001346897.1:c.2438= NM_001346897.1:c.2438T>A NM_001346897.1:c.2438T>G
epidermal growth factor receptor isoform a precursor NP_005219.2:p.Leu858= NP_005219.2:p.Leu858Gln NP_005219.2:p.Leu858Arg
epidermal growth factor receptor isoform g precursor NP_001333828.1:p.Leu813= NP_001333828.1:p.Leu813Gln NP_001333828.1:p.Leu813Arg
epidermal growth factor receptor isoform h NP_001333829.1:p.Leu805= NP_001333829.1:p.Leu805Gln NP_001333829.1:p.Leu805Arg
epidermal growth factor receptor isoform i precursor NP_001333870.1:p.Leu591= NP_001333870.1:p.Leu591Gln NP_001333870.1:p.Leu591Arg
epidermal growth factor receptor isoform f precursor NP_001333827.1:p.Leu858= NP_001333827.1:p.Leu858Gln NP_001333827.1:p.Leu858Arg
epidermal growth factor receptor isoform e precursor NP_001333826.1:p.Leu813= NP_001333826.1:p.Leu813Gln NP_001333826.1:p.Leu813Arg
Help

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

9 SubSNP, 2 Frequency, 12 ClinVar submissions
No Submitter Submission ID Date (Build)
1 OMIM-CURATED-RECORDS ss256302281 Aug 26, 2010 (132)
2 DF-BWCC ss275515310 Nov 22, 2010 (133)
3 ILLUMINA ss1959014474 Feb 12, 2016 (147)
4 CLINVAR ss2137498147 Apr 13, 2017 (150)
5 CLINVAR ss2137504544 Apr 18, 2017 (150)
6 ILLUMINA ss3022737627 Nov 08, 2017 (151)
7 ILLUMINA ss3653270183 Oct 12, 2018 (152)
8 ILLUMINA ss3726446861 Jul 13, 2019 (153)
9 PAGE_CC ss3771372297 Jul 13, 2019 (153)
10 The PAGE Study NC_000007.14 - 55191822 Jul 13, 2019 (153)
11 ALFA NC_000007.14 - 55191822 Apr 26, 2021 (155)
12 ClinVar RCV000018083.89 Oct 12, 2018 (152)
13 ClinVar RCV000018084.63 Oct 12, 2018 (152)
14 ClinVar RCV000150629.1 Oct 12, 2018 (152)
15 ClinVar RCV000211235.1 Oct 12, 2018 (152)
16 ClinVar RCV000211323.1 Oct 12, 2018 (152)
17 ClinVar RCV000211410.1 Oct 12, 2018 (152)
18 ClinVar RCV000418019.1 Oct 12, 2018 (152)
19 ClinVar RCV000419082.1 Oct 12, 2018 (152)
20 ClinVar RCV000435684.1 Oct 12, 2018 (152)
21 ClinVar RCV000987885.1 Apr 26, 2020 (154)
22 ClinVar RCV001030016.1 Apr 26, 2020 (154)
23 ClinVar RCV001030017.1 Apr 26, 2020 (154)
Help

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Added to this RefSNP Cluster:
Submission IDs Observation SPDI Canonical SPDI Source RSIDs
RCV000419082.1, ss2137498147, ss2137504544 NC_000007.14:55191821:T:A NC_000007.14:55191821:T:A (self)
ss1959014474, ss3022737627, ss3653270183 NC_000007.13:55259514:T:G NC_000007.14:55191821:T:G (self)
RCV000018083.89, RCV000018084.63, RCV000150629.1, RCV000211235.1, RCV000211323.1, RCV000211410.1, RCV000418019.1, RCV000435684.1, RCV000987885.1, RCV001030016.1, RCV001030017.1, 593766, 8982940174, ss256302281, ss275515310, ss3726446861, ss3771372297 NC_000007.14:55191821:T:G NC_000007.14:55191821:T:G (self)
Help

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

49 citations for rs121434568
PMID Title Author Year Journal
15118073 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ et al. 2004 The New England journal of medicine
15118125 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG et al. 2004 Science (New York, N.Y.)
15329413 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W et al. 2004 Proceedings of the National Academy of Sciences of the United States of America
15897572 Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY et al. 2005 Clinical cancer research
15901872 EGFR mutation and response of lung cancer to gefitinib. Toyooka S et al. 2005 The New England journal of medicine
16043828 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA et al. 2005 Journal of clinical oncology
16115929 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Taron M et al. 2005 Clinical cancer research
16203769 Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Tomizawa Y et al. 2005 Clinical cancer research
16204011 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Bell DW et al. 2005 Journal of clinical oncology
16204070 Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Jiang J et al. 2005 Cancer research
16865253 Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Endo K et al. 2006 Oncology reports
16956694 Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Han SW et al. 2006 Lung cancer (Amsterdam, Netherlands)
17047654 Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Oshita F et al. 2006 British journal of cancer
17106442 Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Sutani A et al. 2006 British journal of cancer
17192902 The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Ichihara S et al. 2007 International journal of cancer
17285735 Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Sequist LV et al. 2007 The oncologist
17317677 Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Hirsch FR et al. 2007 Annals of oncology
17387341 Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Satouchi M et al. 2007 British journal of cancer
17429313 Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Han SW et al. 2007 Pharmacogenetics and genomics
17473659 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Wu YL et al. 2007 Journal of thoracic oncology
18303429 Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. Marks JL et al. 2008 Journal of thoracic oncology
18349398 Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Miller VA et al. 2008 Journal of clinical oncology
19096302 Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. Kosaka T et al. 2009 Journal of thoracic oncology
19455431 In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs. Rajasekaran R et al. 2010 Applied biochemistry and biotechnology
19692680 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS et al. 2009 The New England journal of medicine
19692684 Screening for epidermal growth factor receptor mutations in lung cancer. Rosell R et al. 2009 The New England journal of medicine
19922469 Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. Mitsudomi T et al. 2010 The FEBS journal
20022809 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Mitsudomi T et al. 2010 The Lancet. Oncology
20038723 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Douillard JY et al. 2010 Journal of clinical oncology
20479403 Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. Sequist LV et al. 2010 Journal of clinical oncology
20573926 Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. Maemondo M et al. 2010 The New England journal of medicine
21670455 Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M et al. 2011 Journal of clinical oncology
21783417 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Zhou C et al. 2011 The Lancet. Oncology
21900837 Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. Goto K et al. 2012 Journal of thoracic oncology
21969500 Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. Brugger W et al. 2011 Journal of clinical oncology
22215752 Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Su KY et al. 2012 Journal of clinical oncology
22370314 First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Han JY et al. 2012 Journal of clinical oncology
22452895 Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Yang JC et al. 2012 The Lancet. Oncology
22740981 Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Chen YM et al. 2012 Oncology letters
22753918 Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. Ramalingam SS et al. 2012 Journal of clinical oncology
22760226 Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cho SH et al. 2012 Cancer chemotherapy and pharmacology
22982650 Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J et al. 2012 Journal of thoracic oncology
22992668 Pharmacogenomics knowledge for personalized medicine. Whirl-Carrillo M et al. 2012 Clinical pharmacology and therapeutics
23102728 MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Huang MH et al. 2013 Molecular oncology
23816960 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Sequist LV et al. 2013 Journal of clinical oncology
23948351 Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Shi Y et al. 2013 The Lancet. Oncology
25157968 Prospective enterprise-level molecular genotyping of a cohort of cancer patients. MacConaill LE et al. 2014 The Journal of molecular diagnostics
26490356 Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Sheng M et al. 2016 European journal of clinical pharmacology
26619011 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Chang MT et al. 2016 Nature biotechnology
Help

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:
Select flank length:

Genomic regions, transcripts, and products
Top Help

NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Software version is: 2.0.1.post596+ae089ad